AstraZeneca (NASDAQ: AZN) reported Q1 EPS of $1.89, $1.06 better than the analyst estimate of $0.83. Revenue for the quarter came in at $11.4 billion versus the consensus estimate of $10.99 billion.

For earnings history and earnings-related data on AstraZeneca (AZN) click here.